 |
|
|
| |
No Impact of Cirrhosis on Mericitabine (MCB) Pharmacokinetics and Early Antiviral Activity in Hepatitis C-Infected Patients Receiving MCB plus Peginterferon Alfa-2A (40KD)/Ribavirin (P/R)
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
S. Moreira,1 M. Levi,1 R. Kulkarni,2 A. Ackrill,3 Y. Zhu,2 J. Thommes,2 Y-C. Chen1
1Hoffmann-La Roche Inc, Nutley, NJ, USA; 2Genentech, South San Francisco, CA, USA; 3Roche Products Ltd, Welwyn, United Kingdom
|
| |
|
|
|
|
|
